These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Regorafenib in glioblastoma recurrence: A case report. Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098 [TBL] [Abstract][Full Text] [Related]
14. The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Rutkowski P; Stępniak J Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387 [TBL] [Abstract][Full Text] [Related]
15. The development of regorafenib and its current and potential future role in cancer therapy. Davis SL; Eckhardt SG; Messersmith WA; Jimeno A Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625 [TBL] [Abstract][Full Text] [Related]
16. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960 [TBL] [Abstract][Full Text] [Related]
17. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature. De Felice M; De Marinis P; Martin G; Bruscella S; De Bellis A; Poliero L; Turitto G Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5008-5013. PubMed ID: 35916797 [TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
20. Characterization of Glioblastoma Cells Response to Regorafenib. Mongiardi MP; Buccarelli M; Formato A; Orecchini E; Salbini M; Ricci V; Orsini T; Putti S; Chiesa S; Ricci-Vitiani L; D'Alessandris QG; Pallini R; Levi A; Falchetti ML Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]